MEP1A contributes to tumor progression and predicts poor clinical outcome in human hepatocellular carcinoma
Han‐Yue OuYang, Jing Xu, Jun Luo, Ru‐Hai Zou, Keng Chen, Yong Le, Yong‐Fa Zhang, Wei Wei, Rong‐Ping Guo, Ming Shi – 13 December 2015 – Although many staging classifications have been proposed for hepatocellular carcinoma (HCC), determining a patient's prognosis in clinical practice is a challenge due to the molecular diversity of HCC. We investigated the relationship between MEP1A, a candidate oncogene, and clinical outcomes of HCC patients; furthermore, we explored the role of MEP1A in HCC.